… ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide … ® EONs are designed to recruit an endogenously expressed RNA editing system called ADAR (Adenosine Deaminase Acting on …
… Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing LEIDEN, Netherlands & CAMBRIDGE, Mass., March 14, … invests in expanding its IP estate around ADAR-mediated RNA editing. “ProQR owns a robust intellectual property …
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will present new preclinical data for its proprietary Axiomer™ RNA editing
ProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leading to meaningful changes in biomarkers in NHPs using Axiomer™ RNA Editing OligonucleotidesPreclinical proof of concept for the Company’
LEIDEN, Netherlands & CAMBRIDGE, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that it will
… ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration with Lilly … to up to five targets u sing ProQR’s proprietary Axiomer ® RNA editing platform ProQR to receive $ 5 0 million …